

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
04 August 2022 (04.08.2022)



(10) International Publication Number
WO 2022/165258 A1

(51) International Patent Classification:

A61K 39/395 (2006.01) A61P 35/00 (2006.01)
C07K 16/30 (2006.01)

(21) International Application Number:

PCT/US2022/014423

(22) International Filing Date:

28 January 2022 (28.01.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/142,832 28 January 2021 (28.01.2021) US

(71) Applicant: **NEXTPPOINT THERAPEUTICS, INC.**
[US/US]; 450 Kendall Street, 5th Floor, Cambridge, Mass-
achusetts 02142 (US).

(72) Inventors: **CHAPPEL, Scott**; c/o NextPoint Therapeutics,
Inc., 450 Kendall Street, 5th Floor, Cambridge, Massachu-
setts 02142 (US). **BINISZKIEWICZ, Detlev**; c/o Next-
Point Therapeutics, Inc., 450 Kendall Street, 5th Floor,
Cambridge, Massachusetts 02142 (US). **ETEMAD-GIL-
BERTSON, Bijan**; c/o NextPoint Therapeutics, Inc., 450
Kendall Street, 5th Floor, Cambridge, Massachusetts 02142
(US). **BOLAND, Nadthakarn**; c/o Adimab, LLC, 7 Lucent
Drive, Lebanon, New Hampshire 03766 (US). **NIELSON,
Nels**; c/o Adimab, LLC, 7 Lucent Drive, Lebanon, New
Hampshire 03766 (US). **PRINZ, Bianka**; c/o Adimab,
LLC, 7 Lucent Drive, Lebanon, New Hampshire 03766
(US).

(74) Agent: **ADAMS, Melissa M.** et al.; Choate, Hall & Ste-
wart LLP, Two International Place, Boston, Massachusetts
02110 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,

NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,

GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a
patent (Rule 4.17(ii))

Published:

— with international search report (Art. 21(3))

(54) Title: HHLA2 BINDING AGENTS WITH NOVEL ACTIVITY

Ab-60638 VH QVQLVQSGAEVKKPKG SVRVSCKASGV FETBYAMHNYROAPGGRTERMGWLNAGTNTKVSQKFOGRVT
Ab-60665 VH QVQLVQSGAEVKKPKG SVRVSCKASGV SSNYALSNVRQAPGGGLEWMEGIIPIIFCANVAQKFOGRVT
Ab-60638 VH RDTSASTAYNELSSLRSEDTAVYYCAR DLPHRGAFIPWGQGTIVTVSS
Ab-60665 VH ADISTSTAYNELSSLRSEDTAVYYCAR S--GTIWHIIPWGQGTIVTVSS

Heavy chains

FIG. 1A

(57) Abstract: The present disclosure pertains to HHLA2 binding agents with novel activity and uses thereof.



WO 2022/165258 A1